Antivirale Therapie – Mechanismen, Substanzen, Anwendung

Bernd Salzberger; Florian Hitzenbichler

doi:10.1055/a-0987-8372

Krankenhaushygiene up2date, Table of Contents

Krankenhaushygiene up2date 2020; 15(02): 135-150
DOI: 10.1055/a-0987-8372

Antiinfektiva

Antivirale Therapie – Mechanismen, Substanzen, Anwendung

Bernd Salzberger

,

Florian Hitzenbichler

Subject Editor: Wissenschaftlich verantwortlich gemäß Zertifizierungsbestimmungen für diesen Beitrag ist Prof. Dr. Bernd Salzberger, Regensburg.

Abstract

All articles of this category

Die ersten antiviralen Substanzen wurden in den 1960er-Jahren entwickelt – also erst sehr viel später als Antibiotika. Der Ausbruch von HIV und der Fortschritt der dadurch eingeleiteten Forschung führten zur Entwicklung vieler neuer antiviraler Substanzen. Heute ist deren Liste länger als die von Antibiotika. In dieser Übersicht werden wichtige Prinzipien der antiviralen Therapie erläutert, Angriffspunkte und antivirale Substanzen vorgestellt sowie zukünftige Entwicklungen skizziert.

Full Text

References

Literatur
1 Prusoff WH. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim Biophys Acta 1959; 32: 295-296
2 Bryson YJ, Dillon M, Lovett M. et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med 1983; 308: 916-921
3 Mullis K, Faloona F, Scharf S. et al. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harb Symp Quant Biol 1986; 51: 263-273
4 De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev 2016; 29: 695-747
5 Sedeyn K, Saelens X. New antibody-based prevention and treatment options for influenza. Antiviral Res 2019; 170: 104562
6 Deutsche AIDS-Gesellschaft (DAIG). Deutsch Oesterreichische Leitlinien zur antiretroviralen Therapie der HIV 1 Infektion. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. AWMF-Register-Nr.: 048-011. Im Internet: (Stand: 06.04.2020) https://www.awmf.org/uploads/tx_szleitlinien/048-011l_S2k_antiretrovirale_Therapie_der_HIV_Infektion_bei_Kindern_Jugendlichen_2019-12.pdf
7 Ayoki FY. Antivirals against Herpesviruses. In: Bennett J, Dolin R, Blaser MJ. Hrsg. Mandell, Douglas, and Bennett´s Principles and Practices of Infectious Diseases. Philadelphia: Elsevier; 2015
8 Boeckh M, Bowden RA, Goodrich JM. et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358-1364
9 Boeckh M, Gallez-Hawkins GM, Myerson D. et al. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997; 64: 108-113
10 European Association for the Study of the Liver (EASL). EASL 2017 Guidelines for the Management of Hepatitis B. J Hepatol 2017; 67: 370-398
11 Fischl MA, Richman DD, Grieco MH. et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185-191
12 Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 1994; 343: 871-881
13 Ho DD, Neumann AU, Perelson AS. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126
14 Hammer SM, Squires KE, Hughes MD. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-733
15 Egger M, May M, Chene G. et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. The Lancet 2002; 360: 119-129
16 World Health Organization (WHO). Update of Recommendations on First- and Second Line Antiretroviral Regimens. Geneva, Schweiz: WHO; 2019
17 Lohmann V, Korner F, Koch J. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113
18 Lindenbach BD, Evans MJ, Syder AJ. et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626
19 European Association for the Study of the Liver (EASL). EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018; 69: 461-511
20 Sarrazin C, Zimmermann T, Berg T. et al. Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection. AWMF-Register-Nr.: 021/012. Z Gastroenterol 2018; 56: 756-838
21 Uyeki TM, Bernstein HH, Bradley JS. et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis 2019; 68: e1-e47